Deutsche Bank raised the firm’s price target on Elevance Health (ELV) to $332 from $320 and keeps a Hold rating on the shares. The firm says the company’s 2026 outlook “may represent a floor.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $396 from $414 at Guggenheim
- Elevance Health Earnings Call Flags Reset Before Rebound
- Elevance Health sees FY26 operating cash flow ‘at least’ $5.5B
- Elevance Health reports Q4 adjusted EPS $3.33, consensus $3.09
- Elevance Health sees FY26 adjusted EPS ‘at least’ $25.50, consensus $26.80